Author

M. Bilen

h-index 4 View on Semantic Scholar

We have 2 of 27 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis.

INTRODUCTION/BACKGROUND Metastatic castration resistant prostate cancer (mCRPC) is a life-limiting phase marked by progression despite androgen deprivation therapy (ADT) with a median overall survival (OS) of approximately 25 months. Gemcitabine plus docetaxel (GEMDOC) has antitumor activity in other solid tumors, but...

J. Ciuro, Ahmet Yildirim, Yuan Liu et al. · Clinical Genitourinary Cance... · 0 citations

Open access Aug 2026

TLSB-25 SINGLE-CELL CHARACTERIZATION OF RENAL CELL CARCINOMA BRAIN METASTASIS

RCC BM represents a biologically distinct tumor entity shaped by neural adaptation, metabolic reprogramming, and immune dysfunction, and supported clinical trials approval testing lenvatinib plus pembrolizumab and zanzalitinib in RCC BM patients.

M. I. Ali, Z. Akpinar, Jose A. Ovando-Ricardez et al. · Neuro-Oncology Advances · 0 citations